Abstract:As an effective target in abnormal angiogenesis-related tumor treatment, VEGFR-2 has small-molecule inhibitors of various scaffolds being approved for treating diseases such as renal carcinoma, non-small cell lung cancer, etc. However, endogenous and acquired drug resistance are still considered to be the main contributors for the failure of VEGFR-2 clinical candidates. Therefore, development of novel VEGFR-2 inhibitors is still urgently needed in the market but also challenging. In this work, residues including Asp1046, Ile1025, HIS1026, Cys919 and Lys868 were identified as the most important residues for Hbonded interaction, while His1026, Asp1046, Glu885, Ile1025 and Leu840 exhibited critical role for the nonbonded interactions through a comprehensive analysis of protein–ligand interactions, which plays critical roles in the binding of compounds and targets. Guided by the analysis of binding interactions, a total of 10 novel VEGFR-2 inhibitors based on N-methyl-4-oxo-N-propyl-1,4-dihydroquinoline-2-carboxamide scaffold were discovered through fragment-based drug design and structure-based virtual screening, which expands the chemical space of current VEGFR-2 inhibitors. Biological activity evaluation showed that even though the enzymatic activity of these compounds against VEGFR-2 were inferior to that of the positive controls sorafenib and motesanib, compound I-10 showed moderate HepG2 cell inhibitory activity with an IC50 value of 33.65 μM and eight compounds exhibited moderate or higher HUVEC inhibitory activity in the range of 19.54–57.98 μM compared to the controls. Particularly, the HUVEC inhibitory activity of compound I-6 (IC50 = 19.54 μM) outperformed motesanib and can be used as starting points for further optimization and development for cancer treatment. Communicated by Ramaswamy H. Sarma

Discovery of Novel Anti-Angiogenesis Agents. Part 7: Multitarget Inhibitors of VEGFR-2, TIE-2 and EphB4.

Discovery of Novel Anti-Angiogenesis Agents. Part 6: Multi-targeted RTK Inhibitors

Discovery of Novel Anti-Angiogenesis Agents. Part 10: Multi-target Inhibitors of VEGFR-2, Tie-2 and EphB4 Incorporated with 1,2,3-Triazol

Discovery of Novel Anti-Angiogenesis Agents. Part 8: Diaryl Thiourea Bearing 1H-Indazole-3-amine As Multi-Target RTKs Inhibitors

Discovery of Novel Anti-Angiogenesis Agents. Part 9: Multiplex Inhibitors Suppressing Compensatory Activations of RTKs

Discovery of multi-target receptor tyrosine kinase inhibitors as novel anti-angiogenesis agents

Discovery and Evaluation of Triple Inhibitors of VEGFR-2, TIE-2 and EphB4 As Anti-Angiogenic and Anti-Cancer Agents

Discovery of Novel VEGFR-2 Inhibitors. Part 5: Exploration of Diverse Hinge-Binding Fragments Via Core-Refining Approach

Discovery of biphenyl-based VEGFR-2 inhibitors. Part 3: design, synthesis and 3D-QSAR studies.

New Application of Novel Tetrazine Derivatives As Potent VEGFR-2 Kinase Inhibitors and Anti-Cancer Agents

Discovery of 6-Arylurea-2-arylbenzoxazole and 6-Arylurea-2-arylbenzimidazole Derivatives As Angiogenesis Inhibitors: Design, Synthesis and in Vitro Biological Evaluation.

Design, Synthesis and in Vitro Evaluation of 6-Amide-2-aryl Benzoxazole/benzimidazole Derivatives Against Tumor Cells by Inhibiting VEGFR-2 Kinase.

Discovery of novel amide derivatives against VEGFR-2/tubulin with potent antitumor and antiangiogenic activity

Discovery of Biphenyl-Aryl Ureas As Novel VEGFR-2 Inhibitors. Part 4: Exploration of Diverse Hinge-Binding Fragments

Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazo-line and diarylamide fragments

Design, Synthesis, Biological Evaluation of Benzoyl Amide Derivatives Containing Nitrogen Heterocyclic Ring As Potential VEGFR-2 Inhibitors

Discovery of Novel Picolinamide-Based Derivatives As Novel VEGFR-2 Kinase Inhibitors: Synthesis,in Vitrobiological Evaluation and Molecular Docking

Protein–ligand Interaction-Guided Discovery of Novel VEGFR-2 Inhibitors

Discovery of Novel Taspine Derivatives As Antiangiogenic Agents.

Design, synthesis and biological evaluation of biphenyl urea derivatives as novel VEGFR-2 inhibitors

Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect